| Outcome Measures: |
Primary: AUC0-24h,sema,day10, area under the semaglutide plasma concentration time curve from 0 to 24 hours after the 10th dosing, Calculated based on semaglutide measured in blood., 0 to 24 hours on day 10 | Secondary: Cmax,sema,day10, maximum observed semaglutide plasma concentration from 0 to 24 hours after the 10th dosing, Calculated based on semaglutide measured in blood., 0 to 24 hours on day 10|tmax,sema,day10, time to maximum observed semaglutide plasma concentration from 0 to 24 hours after the 10th dosing, Calculated based on semaglutide measured in blood., 0 to 24 hours on day 10|AUC0-30min,sema,day10, area under the semaglutide plasma concentration time curve from 0 to 30 minutes after the 10th dosing, Calculated based on semaglutide measured in blood., 0 to 30 minutes on day 10|t½,sema,day10, terminal half-life of semaglutide up to 35 days after the 10th dosing, Calculated based on semaglutide measured in blood. Measured from the 10th. dosing (on Day 10) and up to 35 days after the 10th. dosing (i.e. Day 45)., Days 10-45|Number of treatment emergent adverse events, Count of events., Days 1-47
|
